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Carlos Bernal-Mondragón1, Selva Rivas-Arancibia1, Keith M Kendrick2* and Rosalinda Guevara-Guzmán1*Abstract
Background: Some neurodegenerative diseases, such as Alzheimer and Parkinson, present an olfactory
impairment in early stages, and sometimes even before the clinical symptoms begin. In this study, we assess the
role of CA1 hippocampus (structure highly affected in Alzheimer disease) subfield in the rats’ olfactory behavior,
and the neuroprotective effect of 17 beta estradiol (E2) against the oxidative stress produced by the injection of
amyloid beta 25–35.
Results: 162 Wistar rats were ovariectomized and two weeks after injected with 2 μl of amyloid beta 25–35
(A-β25–35) in CA1 subfield. Olfactory behavior was evaluated with a social recognition test, odor discrimination, and
search tests. Oxidative stress was evaluated with FOX assay and Western Blot against 4-HNE, Fluoro Jade staining
was made to quantify degenerated neurons; all these evaluations were performed 24 h, 8 or 15 days after A-β25–35
injection. Three additional groups treated with 17 beta estradiol (E2) were also evaluated. The injection of A-β25–35
produced an olfactory impairment 24 h and 8 days after, whereas a partial recovery of the olfactory behavior was
observed at 15 days. A complete prevention of the olfactory impairment was observed with the administration of
E2 two weeks before the amyloid injection (A-β25–35 24 h + E2) and one or two weeks after (groups 8 A-β +E2 and
15 A-β +E2 days, respectively); a decrease of the oxidative stress and neurodegeneration were also observed.
Conclusions: Our finding shows that CA1 hippocampus subfield plays an important role in the olfactory behavior
of the rat. The oxidative stress generated by the administration of A-β25–35 is enough to produce an olfactory
impairment. This can be prevented with the administration of E2 before and after amyloid injection. This suggests
a possible therapeutic use of estradiol in Alzheimer’s disease.
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Olfactory disfunctionBackground
Alzheimer’s disease (AD), the most common neurodegen-
erative disorder in humans, is characterized by deterior-
ation of cognitive and mental functions, including learning
and memory skills; particularly those involving medial tem-
poral lobe regions, such as the hippocampus [1]. Interest-
ingly, odor perception and learning, which also involve
medial temporal lobe structures, are often impaired early
in the course of AD, and therefore olfactory processing* Correspondence: k.kendrick.uestc@gmail.com; rguevara@unam.mx
2Key Laboratory for Neuroinformation, School of Life Science & Technology,
University of Electronic Science & Technology of China (UESTC), 610054,
Chengdu, P.R. China
1Departamento de Fisiología, Facultad de Medicina, Universidad Nacional
Autónoma de México. Apdo, Postal 70250, D.F. México, Delegación
Coyoacán 04510, Mexico
© 2013 Bernal-Mondragón et al.; licensee BioM
Creative Commons Attribution License (http:/
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[2-4]. Studies have generally reported olfactory discrimin-
ation and learning deficits early in AD [5,6] followed by
additional problems in detecting odors as the disease pro-
gresses [5,7]. There are many studies reporting the relation
of olfaction impairment with different neurodegenerative
diseases such as Parkinson, Alzheimer and Huntington.
Devanand [8] reported that individuals who had
presented olfactory dysfunction in the UPSIT test, two
years later developed AD. The relationship between
olfactory impairment and cognitive deficit in some neu-
rodegenerative diseases such as Alzheimer has been
well described, but the underlying mechanism of this
relationship is unclear [9]. It has been shown that AD
is characterized by the formation of extracellular de-
posits of A-β peptide [10] leading to the formation ofed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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of hiperphosphorylated tau protein, as well as by the
microglia activation [11] in cortex and hippocampus.
It has been reported that one of the action mecha-
nisms of A-β is through oxidative stress [12,13]. Sev-
eral authors have used the A-β1–42 peptide in animal
models to study AD. However, the fragment 25–35 of
A-β seems to be the neurotoxic part of the whole pro-
tein. This fragment is capable of producing oxygen
species that lead to neurodegeneration by oxidative
stress production only [12,14]. In hippocampus, the in-
jection in CA1 results in a neuronal degeneration and
cell loss of the pyramidal cell layer affecting spatial
memory in rats [15].
A-β25–35 cannot be produced through typical APP pro-
cessing, but it is often selected as an alternative model to
full-length A-β because it retains both its physical and bio-
logical properties. Perhaps the most important factor
which was found to influence toxicity, however, was the
aggregation state forming fibrils with β-structure and
retaining the toxicity of the full-length peptide [16-19]. A-
β25–35, though not present in humans, is widely used by
researchers instead of endogenous fragment A-β1–42,
which is not found to be at least as toxic as the full-length
fragment [14,20].
The first reports on in vivo A-β25–35 were from a series
of studies made by Maurice 1996 [21] and Delobette in
1997 [22] who demonstrated amnesia in mice and rats
injected with this fragment. Likewise, long term or single
A-β25–35 i.c.v injection induced a decline in social recogni-
tion behavior in rats [15,23,24] as well as impaired learn-
ing in a water maze test [21,22,25] and working memory
in a Y maze or radial arm maze [15,21,26-28].
A useful animal model for investigating effects of A-β
protein in AD has been to inject different versions of it
directly into the brain. Thus, we are using in this project
the A-β25–35 fragment in an olfactory behavior paradigm.
To the best of our knowledge, no studies have so far in-
vestigated the effects of this fragment on olfactory per-
ception and memory.
Estrogen is thought to play a protective role against
neurodegeneration through a variety of mechanisms and
to influence cognitive processes such as learning and
memory. The mechanisms implicated include the activa-
tion of growth factors, the control of synaptic plasticity
and reduced effects of toxicity [29]. There is some evi-
dence to suggest that exposure to estrogen decreases the
risk and delays the onset and progression of AD, most
probably by reducing A-β production [30,31]. It has also
been reported E2 inhibits generation of superoxide radi-
cals, thus preventing further propagation of reactive oxy-
gen species (ROS) [32]. It has also been shown to interfere
both with A-β production and clearance in vitro and
in vivo in murine models [33].In the present study, we have therefore investigated first
whether A-β25–35 injected directly into the hippocampus
(HIPP) or into the olfactory bulb (OB) in ovariectomized
female rats produced both neurodegenerative changes in
these regions and impaired olfactory perception and learn-
ing as well as spatial memory (spontaneous alternation).
And secondly, whether treating animals with E2 can pre-
vent some or all of these effects.
Methods
Subjects
Adult female Wistar rats were used in the study. They
were group-housed (4–5 per cage) with food and water
available ad libitum and with an artificial 12 h light/dark
regime (lights were on from 7 am to 7 pm). All experi-
ments and animal welfare conditions were approved by
the Ethical Committee of the Faculty of Medicine at the
Universidad Nacional Autónoma de México and in
accordance with the European Communities Council
Directive. All efforts were made to minimize the number
and suffering of animals used.
A total of 162 adult virgin female three-month Wistar
rats from our house breeding colony were used as sub-
jects and further 63 (20–22 days old) juvenile animals
were used as test stimuli in the social recognition task.
Adults weighed 248.42 g ±12.6 g and juveniles 112 ±
6.48 g. The adult animals were ovariectomized under gen-
eral anesthesia (ketamine/xylazine mixture, 15 mg/kg + 1
mg/kg, i.p) 15 days prior to the experimental procedure.
In order to minimize the number of juvenile animals
used, they were rotated for control and experimental
groups. Adult and juvenile animals were caged individu-
ally 1 h prior to the social recognition tests and during
the 60 min inter exposure interval. All the experiments
were conducted during the light phase of the cycle, be-
tween 0700 h and 1300 h.
Injection of A-β
Stereotaxic surgery: All ovariectomized adult female
Wistar rats were anesthetized with a ketamine/xylazine
mixture (15 mg/kg + 1 mg/kg, i.p) and stereotaxic sur-
gery was performed in a standard rodent stereotaxic
frame (David Kopf, USA). The animals were divided into
six control and twelve experimental groups (n = 9 ani-
mals per group) for the stereotaxic surgery. Three con-
trol groups were assigned for bilateral injection of
phosphate buffer solution in HIPP and three more for
OB, tested 24 h, 8 and 15 days after vehicle injection for
social recognition behavior. Three experimental groups
were injected with 2 μl of A-β25–35 (1 μg/100 μM)
dissolved in phosphate buffer and previously incubated
at 37°C in a shaking-water bath for 72 h (to induce
aggregation state) into the HIPP, tested 24 h, 8 or 15 days
after A-β25–35 injection and other three groups were
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s.c. daily injections for two weeks or one or two additional
weeks (groups evaluated 8 days + E2 or 15 days + E2 after
A- β25–35 injections respectively) and using propylene glycol
as a vehicle. As a control for the E2 injections, three addi-
tional groups received daily injections with the vehicle (sub-
cutaneously propylene glycol) for two weeks and afterwards
for one or two weeks (same as described in upper para-
graph for E2 injections) (See Figure 1). Co-ordinates for
HIPP A-β25-35 and control injections were 4.2 mm poster-
ior to Bregma, 3.0 mm lateral from midline and 2.6 mm
ventral to dura [34]. Another six experimental groups
received a bilateral injection of the A-β in the OB’s co-
ordinates: 7.1 mm rostral to bregma, 1.5 mm lateral to
the midline, and 1.5 mm ventral to dura [34]. Three of
these groups also received E2 for two weeks and one or
two weeks after, prior to A-β injection and tested ei-
ther 24 h, 8 or 15 days later (same as HIPP groups);
other groups received vehicle injections for two weeks
and one or two weeks after A-β25–35 injection. After
recovery from surgery, animals were housed together
in groups. After behavioral testing was completed, the
animals were sacrificed by decapitation and their
brains removed and stored at -80°C for subsequent
analysis.
Social recognition memory test
The social recognition procedure was similar to that de-
scribed in our previous papers [35,36]. The protocol
used was as follows: starting two days prior to A-β or
control vehicle injection in HIPP or OB and just before
the test, each adult rat was habituated to the test cage
daily for four minutes (50X50X42 cm). Each testingTwo weeks Two weeks
Figure 1 Scheme of time line of the procedure used. All rats were ovar
was made. All experimental groups were pre-treated with 17 beta estradio
8 or 15 days + E2 groups received one or two weeks respectively additiona
24 h, 8 or 15 days after A-β25–35 injection.session consisted of a sequence of three 4-min trials.
The first trial for the adult rat was a habituation period
to the test cage; the second trial was the first encounter
between the adult rat and the juvenile rat (social mem-
ory acquisition); the third trial was a re-exposure to the
familiar animal together with an unfamiliar juvenile
stimulus animals introduced simultaneously into the test
cage 60 min after the social memory acquisition trial
(IEI). Experimental groups were tested 24 h, 8 and
15 days after A-β25–35 injection into either HIPP or OB
with or without E2 treatment. Following each test, the
cage was thoroughly cleaned. Video recording of investi-
gatory behavior was used to assess the time spent by
adult rats investigating the stimulus animal in the social
recognition test. The data collected from video-recordings
were transferred to an IBM computer for off-line analysis.
Behaviors considered related to social recognition learn-
ing and memory were anogenital sniffing, close follow-
ing, and pawing of the stimulus animal. The percentage
of time investigating the familiar compared to that with
the unfamiliar one was measured [37]. A selective rec-
ognition memory was considered present if there was
first, a significant reduction in the mean duration time
of exploration, between the first two encounters with
the stimulus juvenile; and, secondly, if there was also
significantly greater investigation time of the novel ju-
venile in the third trial compared with that for the fa-
miliar juvenile.
Olfactory perception and habituation tests
To test for possible general olfactory perception impair-
ments, additional groups of ovariectomized animals were









iectomized and let them recover for two weeks before any procedure
l (E2) (25 μg/kg) for two weeks before A-β25–35 injection in HIPP or OB.
l injections of E2. Olfactory tests and brain extraction were carried out
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after 24 h, other groups were A-β25–35 injected and
tested at 24 h, 8 and 15 days later (independent groups).
Another group was pre-treated with E2 for two weeks
prior to A-β injection (A-β25–35 + E2, 24 h group). Two
additional groups were injected additionally with E2 for
one or two weeks, after A-β25–35 injection (A-β25–35 +
E2, 8 days and A-β25–35 + E2, 15 day groups). For the
olfactory perception test, individual animals were tem-
porarily transferred from their home cage to another
acrylic box and placed in the center, while a small piece
of chocolate was buried in a random corner in the bed-
ding of their home cage. Each animal was tested once
and then returned to its home cage. The time it took
them to locate and eat the chocolate chip was recorded
(latency (up to a maximum of 120 s)). Latency to locate
the buried piece of chocolate was the dependent variable
in this analysis.
After the social recognition test was completed, we
also evaluated non-social odor discrimination skills in
all groups (adapted from Paolini and McKenzie) [38]. A
lemon scented filter paper was introduced into a small
perforated tube (5 cm long, 1.5 cm diameter) which
was fixed on one of the walls of the experimental cage
and the animal was allowed to explore it for two mi-
nutes. We repeated this procedure three times with
ten-minute intervals between trials (IEI) and with the
same scent (lemon) (three habituation trials). In the
fourth discrimination trial, a vanilla scent was poured
to the filter paper and the procedure was repeated. In
order to test an odor preference, we also used other
scents such as coffee and orange. We did not observe
any preference or aversion to these odors (data not
shown).Spontaneous alternation behavior in a T-maze
A T-maze test [39] has been widely used to assess spatial
memory in rats. This test analyzes the natural spontan-
eous exploratory behavior of rodents and other species
[40]. We used this test to evaluate effects of A-β25–35 in-
jection into the HIPP. Same control and experimental
groups tested in the social recognition memory detailed
above were used to evaluate effects on spatial memory.
The T maze was made of black painted wood and cov-
ered by clear Plexiglas. Each arm was 30 cm long, 12 cm
wide and 10 cm high. The floor of each arm was covered
with paper, which was changed between trials. Each rat
was placed at the end of one arm and allowed to move
freely through the maze for eight minutes. The number
of arm entries made by the animals, including returns
into the same arm (errors), was visually recorded. Alter-
nation was defined as entries into all three arms on con-
secutive occasions (triplets).Measurement of lipid peroxidation (LPO)
After behavioral tests, control and experimental animals were
sacrificed, their brains were placed on an ice-cold plate and
HIPP, OB and frontal cortex dissected out and weighed im-
mediately after. Each structure was homogenized in PBS 1:20
and divided into two tubes which were stored at −80°C
until the day of the assay for LPO using a FOX assay Kit
or for Western Blot. LPO was measured using the
Peroxidetect kit (Sigma-Aldrich) which measures the col-
ored adduct formed by xylenol orange and Fe3+ generated
in presence of peroxides. Sample lipids were extracted
using the Bligt & Dyer Protocol. For each ml of sample,
3.75 ml 1:2 (v/v) of CHCl3: MeOH was added and mixed.
In a second step, 1.25 ml of CHCl3 was added and mixed,
and then 1.25 ml of dH2O was added and mixed. The
samples were centrifuged at 1000 RPM for five minutes at
room temperature to obtain a two-phase system and from
which the organic phase was recovered. 100 μl of the sam-
ple was placed in a tube; 1 ml of the working color reagent
prepared from the kit was added. The mixture was incu-
bated for 30 minutes at 25°C: the samples were read in a
spectrophotometer at 560 nm using methanol as blank. A
standard curve of t-BuOOH was plotted. Nanomols of
peroxide were calculated using the standard curve and
according to the formula:
LPO value in nmol=ml ¼ Es‐Ebð Þ X50:0= Estdð Þ
X Sample volumeð Þ ðEs ¼ Sample Absorbance;
std ¼ Absorbance of 1 nmol=peroxide from
the standard curve; Eb ¼ Blank absorbanceÞ:
Western blot for 4-hydroxinonenal
A Western Blot assay for quantifying 4-hydroxinonenal
(4-HNE) adduct levels was performed. Proteins were
separated by sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE 10%) and transferred to
nitrocellulose membranes. Membranes were collected
and dried at room temperature until used. The mem-
branes containing the samples (OB or HIPP) were
blocked with 5% skimmed milk in TBS-T = 0.01% of
Tween 20 (TBS-T) for 2 h at 37°C, and incubated with
anti 4-HNE (R&D Systems) (1:1000) overnight under
gentle shaking at 4°C. Membranes were rinsed three
times with TBS-T, and thereafter were incubated with
goat anti-rabbit IgG conjugated with horseradish perox-
idase (1:10,000) (Sta. Cruz) for 1 h followed by three
times rinsing with TBS-T. Recognized bands were visua-
lized by chemiluminiscence (ECL, General Electric).
Fluoro-Jade Staining
Degenerating neurons in HIPP and OB were labeled
using Fluoro-Jade staining. All labeled neurons from the
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each brain were used for statistics. For this technique,
brains were first embedded in paraffin, cut into 7 μm
sections using a microtome and mounted on glass slides.
Slides were then first immersed in a solution containing
1% sodium hydroxide in 80% alcohol (20 mL of 5%
NaOH added to 80 mL absolute alcohol) for five mi-
nutes. This was followed by two minutes in 70% alcohol
and two more minutes in distilled water. The slides
were then transferred to a solution of 0.06% potassium
permanganate for 10 minutes on a shaker table to en-
sure consistent back ground suppression between sec-
tions. They were then rinsed in distilled water for two
minutes. The staining solution was prepared from a
0.01% stock solution for Fluoro-Jade C that was made
by adding 10 mg of the dye powder to 100 mL of dis-
tilled water. To make up 100 mL of staining solution,
4 mL of the stock solution was added to 96 mL of 0.1%
acetic acid vehicle. After 20 minutes in the staining so-
lution, the slides were rinsed for one minute in each of
three distilled water washes. Excess water was removed
by briefly (about 15 s) draining the slides vertically on a
paper towel. The slides were then placed on a slide
warmer set at approximately 50°C, until they were com-
pletely dry. The dried slides were cleared by immersion
in xylene for at least a minute before the analysis. For
analysis, the average numbers of stained cells were
counted in four sections from the HIPP and OB of each
animal. The sections were taken from the coordinates
mentioned above.
Statistics
Behavioral data obtained during the social recognition
task were expressed as ratios (investigation times of
unfamiliar (unfamiliar + familiar)). Because ratios violate
the homogeneity of variance assumption required by
parametric statistics, the duration of social investigation




] [37]. Social investigation times were recorded
for each animal and then these values were averaged
and transformed according to the experimental group.
To test for an overall effect of treatment (A-β25–35 injec-
tion) on the exploration time, a three factor analysis of
variance (ANOVA) was carried out with brain region,
treatment and treatment duration as factors reaching a
significant difference of p < 0.05; post hoc planned
contrast comparisons (corrected for multiple compari-
sons Tukey test) were made using a SPSS 15.0. Effects of
A-β25-35 on discrimination of different odors were tested
using a 4-way ANOVA with brain region (HIPPO/OB),
treatment (vehicle, A-β25–35, E2), treatment duration
(24 h, 8 and 15 days) and odor trials as factors and
followed by post-hoc tests. Effects of A-β25-35 on latencies
to locate buried chocolate, LPO and Fluoro-Jade stainingwere also analyzed using two or three-way ANOVAs. The
results showed a significant statistical difference of
p < 0.05 followed by Tukey post hoc tests.
Results
Figure 2 shows that injection of A-β25–35 in hippocampus
decrease the novel:familiar ratio, increasing the investiga-
tion time for the familiar juvenile in the second encounter;
in the groups evaluated 24 h and 8 days after injection, the
animal is unable to distinguish between the juvenile famil-
iar from the juvenile unfamiliar odor. The administration
of E2 reestablishes the time investigation as control
groups. No effect was observed if the A-β25–35 injection
was applied in the olfactory bulb. A three way ANOVA re-
vealed main effects of treatment (Vehicle, Amyloid beta or
E2) (F2,161 = 5.64, p = 0.004) and treatment duration (24 h,
8 or 15 days) (F2, 161 = 10.771, p < 0.001) but not at brain
region (HIPP or OB) (F1,161 = 0.805, p = 0.371). There were
also significant interactions between treatment and treat-
ment duration (F4,161 = 3.717, p = 0.007) as well as treat-
ment and brain region (F2, 161 = 6.574, p = 0.002) but not
between treatment duration and brain region (F2, 161 =
2.499, p = 0.086). These show that treatment effects oc-
curred mainly in the HIPP, which were also reduced over
time in the HIPP. Finally, there was also a treatment x
treatment duration x brain region interaction (F3, 161 =
2.996, p = 0.033) indicating again that treatment and treat-
ment duration effects mainly occurred in the HIPP rather
than in OB. Post-hoc comparisons revealed there were sig-
nificant differences between HIPP and OB in both 24 h
(p = 0.03) and 8 day (p < 0.001) groups, but no differences
were found between the 15 day treatment groups (p =
0.542, NS). Post-hoc tests revealed that social recognition
memory was significantly impaired by A-β injection in
HIPP in both the 24 h (p < 0.001) and 8 day (p < 0.001)
treatment groups compared with that of control groups
(vehicle). No differences were found with the 15 day treat-
ment group compared with that of the control group (F5,
54 = 4.30 p = 0.73, NS). Pre-treatment with E2 in the HIPP
groups significantly improved olfactory recognition me-
mory in the 24 h (p < 0.001) and 8 day (p < 0.001) groups
compared to those with A-β25–35 alone and to a level
which did not differ significantly from that of controls
(24 h p = 0.73; 8 days p = 0.113). No significant effect was
observed when E2 was injected two weeks before and two
weeks after A-β25–35 injection in the 15 day A-β25–35 + E2
compared with 15 day A-β alone group (p = 0.177 NS).
It called our attention the significant differences ob-
served between the OB vehicle group and A-β25-35 plus
E2 group with the 15 day treatment duration (p = 0.008).
This can be interpreted as a possible influence of estro-
gens in memory.
After A-β25–35 injection in HIPP, the lesion provoked by




















Figure 2 Olfactory memory acquisition. A. Olfactory memory acquisition in social investigation, control group. B. Ratios of time investigating
the familiar or the unfamiliar juvenile rat. Adult ovariectomized female rats tested at 60 min IEI. Control groups (vehicle) evaluated at 24 h, 8 and
15 days after vehicle injection. Experimental groups injected with A-β25-35 and A-β +E2. HIPP (black columns) or OB (grey columns) evaluated at
same times as control groups. *P < 0.05; **P < 0.01; ***P < 0.001, comparison intergroup. +P < 0.05 comparison between OB and HIPP groups.
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a typical cannula placement in the HIPP and Figure 3E
in OB.
Figure 3B and F show mean latencies to locate buried
chocolate in the A-β25-35 injected HIPP and OB groups
and the ones which received additional E2. A three-way
ANOVA revealed main effects of treatment (F2, 89 = 10.25,
p < 0.0001), treatment duration (F2, 89 = 4.90, p < 0.01) and
brain region (F1, 89 = 54.3, p < 0.0001). There was also sig-
nificant interaction between treatment and brain region
(F2,89 = 6.55, p = 0.002) and between treatment duration
and structure (F2,89 = 4.9, p < 0.01) showing that the A-β25-35
treatments, and their duration, had different effects in the
HIPP and in OB. Post-hoc comparisons revealed signifi-
cant increases in latency in the 24 h, 8 days HIPP A-β25-35
groups compared to those of vehicle injected controls or
the A-β25-35 groups treated with E2 (p < 0.05 in all cases)
but no differences between the three A-β25-35 treatment
durations. Indeed, none of the animals were able to find
the chocolate within the 120 s test duration, while all the
animals in the control group succeeded well within this
time. On the other hand, no differences were found be-
tween A-β25–35 injections from A-β25–35 + E2 injection in
the olfactory bulb.
Figures 3C and G show the mean investigation times
in the habituation-dishabituation odor discrimination
paradigm in experimental and control HIPP and OBgroups. They were recorded in tests at 24 h, 8 or 15 days
after A-β25-35 or control injections and for 24 h A-β25-35
treatment preceded by two weeks of E2. A 4-factor
ANOVA with treatment (treatment duration, trials and
brain region as factors) revealed significant main effects
of treatment (F2, 161 = 192.17, p < 0.0001), trial (F3, 647 =
395.3, p < 0.0001) and brain region (F1, 647 = 45.0, p <
0.0001) but not of treatment duration (F2, 647 = 0.93, p =
0.396). There were also significant interactions between
treatment and brain region (F2, 647 = 54.97, p < 0.0001),
treatment and trial (F6, 647 = 33.03, p < 0.0001) and be-
tween trial and brain region (F3, 647 = 2.763, p = 0.041)
and also for treatment x trial x brain region (F6, 647 =
11.11, p < 0.0001). In general, these show that the A-β25-35
treatment only had a significant effect on investigation
times across trials in the HIPP compared with those on
the OB. Post-hoc analysis revealed that both HIPP and OB
(trial 1 p < 0.001 vs. trials 2 and 3 in both cases) control
groups showed a clear habituation to the lemon odor test
across the three trials and a clear dishabituation (trial 4 vs.
trial 3, p < 0.001 in both cases) response was obtained after
presentation of a different odor on trial 4 (vanilla).
For the HIPP experimental groups tested 24 h, 8 or
15 days after A-β injection, no significant habituation
was observed (p > 0.05 in all cases). However, the group
that received E2 pre-treatment before the A-β25-35 in-































































































C 24h A-β 24h A-β 8 Days A-β 15 DaysC 24h A-β 24h A-β 8 Days A-β 15 Days
Hippocampus OlfactoryBulb
25-35
25-35 + E2* *
Figure 3 Behavior test. A and E, Microphotography of HIPPO and OB shows the cannula trajectory (4X). B and F, Graphs show the latency to
find the piece of buried chocolate of ovariectomized animals tested 24 h, 8 and 15 days after HIPPO (B) or OB injection (F). A-β25-35 injection
alone (grey columns). Treatment with E2 (black columns). C and G, Graph shows mean investigation time(s) invested by ovariectomized animals
to habituate/dishabituate to lemon and vanilla odors, experimental groups tested at 24 h, 8 and 15 days after A-β injection in HIPPO and a group
received E2 + A-β (C, graph) or OB (G, graph). D and H, Graphs show percentage of spontaneous alternation triplets in a T-maze of same
experimental (grey columns, A-β groups, black columns A-β + E2 treatment) and control groups, white columns. *P < 0.05, ***P < 0.001.
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and 15 day treatment groups (P < 0.0001 in all cases).
The treated A-β OB groups showed a pattern of ha-
bituation/dishabituation across trials that did not differ
from that of controls (p < 0.05 in all cases).
Figures 3D and H show the effects of HIPP and OB
A-β25-35 and E2 treatments on spontaneous alternation
behavior. There were significant main effects of treatment
(F2, 143 = 15.4, p < 0.0001), treatment duration (F2, 143 =
5.63, p = 0.005) and brain region (F1, 143 = 8.13, p = 0.005).
Significant interactions were found between treatment
and brain region (F2,143 = 25.42, p < 0.0001) and treatment
duration and brain region (F2,143 = 10.68, p < 0.0001) indi-
cating that HIPP treatment effects were greater than those
for OB treatment at 24 h and 8 day time points. Therewas also a significant interaction between treatment and
treatment duration (F2,143 = 18.35, p < 0.0001) indicating
again that treatment effects were only at the 24 h and
8 day time points. Post-hoc tests revealed that A-β in-
jection in the HIPP impaired spontaneous alternation be-
havior at the 24 h and 8 day time points compared with
that of the control group and the group pre-treated with
E2 (p < 0.0001 in all cases). The 24 h E2 pretreated group
and 15 day A-β25-35 treatment groups did not signifi-
cantly differ from the control one (p = 0.26 and 0.92,
respectively).
Figures 4A and 5A show that LPO levels were high in
both HIPPO and OB by 24 h after A-β25-35 injection but
not in the frontal cortex (which was used only as a refe-
rence structure). A three-way ANOVA revealed that levels
GAPDH
Figure 4 Effect of A-β injection in HIPPO. A. Effect of A-β25-35 injection in HIPPO on lipid peroxidation levels in HIPPO, OB and Frontal Cortex
(FC) of ovariectomized animals. Mean ± SEM lipid peroxidation levels in the four experimental groups (24 h, 8 and 15 days groups and 24 + E2).
The lipid peroxidation levels in nanomoles/ml of homogenate HIPPO, OB or FC tissue depicted on the ordinate. Minimal amount of
lipoperoxidation was detected 15 days after A-β25-35 injection. E2 replacement decreases the lipoperoxidation in HIPPO as well as in OB.
B Western blot technique to measure 4-HNE adduct in Hippocampus reflects the lipoperoxidation in HIPPO, OB and FC in the same experimental
groups. The amount of 4-HNE adducts, is related with the presence of peroxides in the structure, the administration of E2 decreases the presence
of peroxides and the amount of 4-HNE.
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http://www.biomedcentral.com/1471-2202/14/104of lipoperoxidation (LPO) varied significantly, with main
effects of treatment (F1, 119 = 20.93, p < 0.0001), treatment
duration (F2, 119 = 46.23, p < 0.0001) and brain region
(F2, 119 = 6.13, p = 0.003). There were also significant inte-
ractions between treatment and brain region (F2,119 = 7.06,
p < 0.001) and between treatment duration and brain region
(F4,119 = 5.05, p < 0.001) indicating that A-β25-35 injections
produced greater effects in the HIPP and OB than in the
frontal cortex. Post-hoc tests showed that the group pre-
treated with E2 showed significantly lower levels of lipo-
peroxidation in both HIPP and OB 24 h after A-β25-35
injection compared to those of the group treated with
A-β25-35 alone for 24 h (p < 0.05 in both cases). The
Western Blot analyses of lipid peroxidation 4-hydroxy-2-
nonenal (4-HNE) protein adduct showed high levels after
A-β25-35 injection in HIPPO and OB but not in the
frontal cortex (Figures 4B and 5B). The A-β25-35 HIPP in-
jection group treated with E2 showed a reduced presence
of 4-HNE (Figure 4B).
Fluoro-Jade staining revealed the presence of degener-
ating neurons in HIPP at 24 h, 8 days and 15 days afterA-β25-35 injection (Figures 6C,D,E and F) but not in the
OB (data not shown). There was also no evidence for
Fluoro-Jade stained degenerating neurons in the HIPP
or OB following OB injection of A-β25-35. A two-way
ANOVA was therefore performed only on the groups
with HIPP injections and with treatment and treatment
duration as factors. This showed significant main effects
of treatment (F1, 15 = 18.67, p < 0.001) but not treatment
duration (F2, 15 = 0.269, p = 0.769). Post-hoc pairwise com-
parisons revealed a significant difference between the 24 h
A-β25-35 injected group and the 24 h A-β group pre-
treated with E2 (p < 0.001). There was also a significant re-
duction in the number of staining cells in the A-β25-35
15 day group compared with the 24 h one (p < 0.05).
Discussion
Our results demonstrate that bilateral injections of the
A-β25-35 fragment in the HIPP of ovariectomized female
rats produce marked deficits in olfactory perception
and social recognition and spatial memory as shown in
Figures 2 and 3. Bilateral injections of the same dose of
A B
GAPDH
Figure 5 Effect of A-β injection in OB. A. Effect of A-β25-35 injection in OB on lipid peroxidation levels in HIPPO, OB and Frontal Cortex (FC) of
ovariectomized animals. Mean ± SEM lipid peroxidation levels in the four experimental groups (24 h, 8 and 15 days and E2 replacement groups).
The lipid peroxidation levels in nanomoles/ml of homogenate HIPP, OB or FC tissue depicted on the ordinate. Significant differences were found
in 24 h experimental group between HIPPO and OB compared with FC tissue. Minimal amount of lipoperoxidation was detected 15 days after
A-β injection in the three structures evaluated. E2 decreases the lipoperoxidation in HIPPO as well as in OB. B. Western blot technique to measure
4-HNE adduct in OB reflects the lipoperoxidation in HIPPO, OB and FC in the same experimental groups. The amount of 4-HNE adducts is related
with the presence of peroxides in the structure, the administration of E2 decreases the presence of peroxides and the amount of 4-HNE.
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http://www.biomedcentral.com/1471-2202/14/104A-β25-35 into the OB did not produce any behavioral im-
pairment. These behavioral effects of HIPP A-25–35 β in-
jections were associated with increased LPO and 4-NE,
in both HIPP and OB; although only with injections
into the HIPP did actual neuronal degeneration occur
in the HIPP, as shown in Figure 4. These behavioral and
degenerative effects of A-β25-35 injection occurred at 24 h
and 8 days after treatment although they had largely dis-
appeared by 15 days post injection. It is important to high-
light that two weeks pre-treatment before A-β25-35
injection, with E2 or one or two weeks after prevented
the occurrence of all perceptual and memory impair-
ments and significantly reduced associated neurode-
generative changes. Thus, E2 treatment can play a
potent role in protecting the brain from the neurotoxic
effects of A-β25-35.
A-β is the main constituent of senile plaques found
in the aging brain and has been extensively linked with
disturbances of learning and memory processingcharacteristics of aging-associated disorders, such as
AD [1,41]. It is also known that aggregation of the
amyloid peptides is responsible for neurotoxicity
[20,42,43].
Up to date, there is no data regarding the formation of
plaques in A-β25–35 injection models. Which was neither
observed in our model in any of the time points being
assessed (24 h, 8 and 15 days). The injections of A-β25-35
did not produce neurodegenerative changes restricted
to the region of the injection. At this point, we are
unsure how the A-β25-35 spread from the HIPP to OB
and vice versa despite simple transport within the
cerebroventricular system seems unlikely due to the
absence of effects in the frontal cortex. Instead, a more
likely explanation is transport along migratory routes
between the two structures. Both HIPP and OB are
sites of neurogenesis within the brain but also where cells
migrate from the sub-ventricular zone into both regions.
[44]. Stem cells applied intranasally have also been shown
Figure 6 Injection sites. A. Scheme of A-β25-35 injection sites (Ca1 subfield). B. Only Fluorojade positive cells staining were counted. C, D, E.
Microphotography’s of HIPPO using Fluorojade staining after A-β25-35 injection in HIPPO and sacrificed at 24 h, 8 or 15 days later. Insert shows 40x
magnification of Ca1 subfield. F, pretreatment two weeks before A-β 25–35 with E2.
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findings may suggest a mechanism where A-β formation
occurring within the OB can rapidly move into the HIPP
and vice versa.
Our finding that both olfactory perception and so-
cial recognition memories were impaired following
A-β25-35 injection into the HIPP was also unexpected
as a previous research work suggested a role for the
HIPP in social recognition memory [46] and other
forms of olfactory memory [47-49] but not in
olfactory perception per se. Possibly, the profound
olfactory perception deficits we observed may have
been caused by the spread of A-β from the HIPP to
the OB, although we did not find similar deficits fol-
lowing direct injection of the same A-β25-35 dose into
the OB despite similar levels of lipoperoxidation.
However, as a result of the olfactory perception defi-
cits, we obviously cannot conclude that social recog-
nition memory was impaired since this is highly
dependent on odor cues [50]. Nevertheless, since def-
icits in a non-odor dependent spatial memory taskspontaneous alternation were also found, we can con-
clude that the A-β25-35 injection into the HIPP im-
paired both olfactory perception and spatial learning.
These data suggest that neurodegeneration in HIPP
could explain in part, olfactory impairment found in
some neurodegenerative diseases such as Alzheimer’s.
Our findings show that oxidative stress due to A-β25-35
injection failed to produce actual neurodegeneration in
the OB which was expected to happen given the effects
observed following HIPP injections. However, there is
evidence that the pyramidal neurons of the CA1 HIPP
subfield are very sensitive to oxidative stress [51] and so
perhaps this may explain why only the HIPP show actual
evidence for neurodegenerative cells thus resulting in
behavioral changes. Other studies have also reported
that A-β25-35 can damage the HIPP and impair learning
and short-term memory [15,52,53]. Another one has
reported that bilateral injection of A-β25-35 into the
amygdala of rats induced histopathological changes
such as the appearance of reactive astrocytes and neu-
ronal shrinkage, but did not cause any disturbance in
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[54]. Interestingly, in agreement with our observations,
spatial memory impairments following intracerebro-
ventricular (i.c.v) injections of A-β25-35 have also been
reported to be correlated with actual neuronal cell loss
in HIPP [53].
LPO is a reliable marker of oxidative stress because it
reflects damage to membranes and produces a variety of
damaging reactive oxidizing species associated with cell
death [55]. For instance, oxidative stress caused by envir-
onmental stimuli is proposed to be involved in brain
neuronal death in many neurodegenerative disorders
such as Alzheimer’s and Parkinson’s diseases [56].
Previous evidence from our laboratory has shown that
ozone inhalation causes oxidative stress in a number of
different brain regions in rats [57,58] and in this paper,
we show that A-β25-35 injection in the HIPP increases
LPO in it as well as in the OB compared with control
groups. It is well known that HIPP is one of the key
sites vulnerable to neurotoxicity in vivo and in relation
to AD [52,59].
Our experiments showed that both behavioral and
neurodegenerative impairments induced by A-β25-35 in-
jections were transient with changes either fading or
disappearing by 15 days post-injection. To the best of
our knowledge, this ability of the brain to largely recover
from the neurotoxic effects of A-β25-35 injections has
not been reported, with most studies focusing on single
time points [15,27,52].
For instance, in the hippocampus, there are reports that
CA1 region neurons are more susceptible to oxidative
stress impairment than CA2 or CA3 neurons [60]. The
aforementioned statement means that even though similar
oxidative levels are produced by the A-β25-35 injection in
both sites HIPP and OB, it results in a neuronal degener-
ation in only the CA1 region of the hippocampus but not
in the that of the olfactory bulb where the olfactory behav-
ior remains intact even after being the A-β25-35 injected
directly in the bulb. In fact, in order to produce an olfac-
tory behavior impairment injecting the A-β25-35 in the OB,
we need to administer a double dosage than that in HIPP
(4 μl), (data not shown), which evidences the susceptible
difference to oxidative stress between hippocampus and
olfactory bulb neurons.
A-β25-35 injection in the hippocampus produces a fluc-
tuation in the spatial behavior [15,61]. In our model, we
found that there are also fluctuations in the rat’s olfactory
behavior; these are observed in the first few days after
A-β25-35 injection as Figures 2 and 3 show. However, a re-
covery of the olfactory behavior is observed afterwards.
It has been reported that cell neurogenesis in the
subventricular area and its migration to the lesion area
may partly explain this recovery [62]. Our injection
model shows that the affected neurons are those foundin an adjacent A-β25-35 injected area, no bigger than 600
microns, thus the impairment does not invade other
areas of the hippocampus keeping the rest of the struc-
ture’s functions intact.
Some studies have reported memory impairments fol-
lowing i.c.v A-β25-35 administration after periods around
or in excess of 15 days [15]. It is possible, therefore, that
the brain’s capacity to compensate following A-β treat-
ment may be increased when localized injections in the
HIPP or OB are used as opposed to more global i.c.v
administration. There is continuous cell migration from
the subventricular and subgranular zones of the HIPP to
the OB and to the HIPP itself following damage [59].
Thus, possibly, cell migration from the subventricular
zone to the OB together with neurogenesis within the
OB contributed to both functional and neurodegenerative
recovery by 15 days after HIPP A-β25-35 injections and
E2 treatment.
The A-β25-35 induced neurodegeneration is traceable by
means of a Fluoro-Jade C technique which is positive from
24 hours after injection. This technique mainly stains the
neurons in degeneration process [63]. This degeneration
will result in cell death and the neuronal remains will
eventually vanish together with the astrogliosis and in-
flammatory reaction. As the Fluoro-Jade C is mainly used
to signal the cells in degeneration process, the intensity of
the signal gathered at day 15 is lesser than that obtained at
24 hours or 8 days later, there are scarcely left few neur-
onal remains, thus, less fluorescence. When we assess
hippocampus cuts stained with eosin and hematoxylin
after 15 days, we can observe the absence of pyramidal
neurons in the injected area.
Neuroprotective actions of estradiol have been shown
in a number of different contexts [29,32]. The 17 β-
estradiol dosage used in this research work has shown
to have antioxidant effects in other models such as the
exposure to ozone [57,58]. In the current study, the
protective effects we observed following a two week
pre-treatment and a one or two weeks after E2 in ovari-
ectomized rats were clearly very strong, with a complete
absence of any olfactory perception or olfactory learning
or spatial learning deficits. While, following the E2 treat-
ment, there was still some evidence for increased
lipoperoxidation and neurodegenerative changes at 24 h
after A-β25-35 treatment in either HIPP or OB; this was
significantly lower compared with that of A-β25-35
treatment alone. There is a significant decrease in the
lipoperoxidation levels after A-β25–35 injection in the
group with estradiol supplement, while in the groups
without it the oxidative stress levels were higher. It can
be observed that the dosage used (25 mg/kg) has an
antioxidant effect which is reflected in a lower neuronal
degeneration which is related to a lesser intensity of the
Fluoro-Jade stain.
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to ovariectomized rats protects against ozone-induced
olfactory memory deficits and lipoperoxidation in the
olfactory system [58]. Here, we have extended these
findings to include protection against the neurodegen-
erative and behavioral effects of A-β.
We deliberately chose to use an ovariectomy model in
order to demonstrate potential neuroprotective effects of E2
treatment since it reflects similar hormonal changes that
occur in women following menopause. While the incidence
of AD is significantly higher in women than in men, clear
evidence that post-menopausal reductions in estrogens
contribute to this as opposed to greater longevity has yet to
be produced [64-66], despite early influential studies sug-
gesting otherwise [30,31]. It does, however, seem that there
may be a particular period of vulnerability in the early
stages of menopause and there is still considerable interest
in establishing potential therapeutic efficacy of estrogen
treatment [64]. At this stage, studies in rodents have re-
ported that brain estrogens deficiency can accelerate A-β
plaque formation in a transgenic mouse model of AD [67].
It also seems to be that both estrogen α and β-receptors
may contribute to increases and decreases respectively in
hippocampal apolipo protein E expression [68]. Further-
more, the potential neuroprotective mechanism whereby
estrogen is acting to reduce A-β may be due to reductions
in oxidative stress via the mitochondria. Clearly, we still
need further evidence to support both estrogen interactions
with A-β injection as well as its potential for therapeutic
use in AD.
Conclusions
In summary, our results have demonstrated significant im-
pairments of olfactory perception and spatial memory func-
tion 24 h and 8 day following injection of A-β25–35 in the
HIPP, but not in the OB of ovariectomized rats. These be-
havioral changes were associated with evidence of high
levels of lipoperoxidation in both HIPP and OB and the
presence of degenerating neurons in HIPP. A two-week
pre-treatment or one or two weeks after with E2 in ova-
riectomized rats completely prevented the occurrence of
behavioral impairments and markedly reduced neurodegen-
erative changes 24 h after A-β25-35 injection into the HIPP.
These results further suggest an important neuroprotective
role for estrogens against A-β25-35 induced neurotoxic dam-
age with potential relevance to treatment of AD, particu-
larly in the context of post-menopausal women.
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